Related Experiment Videos
Cell cycle arrest by Colcemid differs in human normal and tumor cells
M N Jha1, J R Bamburg, J S Bedford
1Department of Radiological Health Sciences, Colorado State University, Fort Collins 80523.
Cancer Research
|September 15, 1994
Summary
Human tumor cells show an immediate increase in mitotic index when treated with Colcemid, unlike normal cells which exhibit a 2-3 hour delay. This suggests a difference in the G2 cell cycle checkpoint between tumor and normal cells.
Area of Science:
- Cell Biology
- Cancer Research
- Pharmacology
Background:
- Cell cycle regulation is crucial for normal cell function and is often dysregulated in cancer.
- Colcemid is a known inhibitor of microtubule polymerization, arresting cells in mitosis.
Purpose of the Study:
- To investigate potential differences in cell cycle regulation between human tumor and normal cell lines.
- To characterize the response of various cell lines to Colcemid treatment.
Main Methods:
- Exposure of nine human tumor and 12 normal cell lines to varying concentrations of Colcemid.
- Monitoring of mitotic index over time following drug addition.
- Comparative analysis with other microtubule-targeting agents like Taxol, nocodazole, and vinblastine.
Main Results:
- Human tumor cell lines exhibited an immediate increase in mitotic index upon Colcemid addition.
- Human normal cell lines displayed a significant delay (2-3 hours) before mitotic index increase.
- This differential response was independent of cell origin and Colcemid concentration range.
- Similar delayed effects were observed with vinblastine, but not Taxol or nocodazole.
Conclusions:
- A fundamental difference exists in the G2 cell cycle checkpoint between human normal and tumor cells.
- This checkpoint operates approximately 1-2 hours prior to mitosis.
- The findings may have implications for understanding cancer cell behavior and developing targeted therapies.